7 Best Peptides for Women in 2026 (Fat Loss, Anti-Aging, and Hormonal Balance)

The 7 best peptides for women ranked by goal: fat loss, anti-aging, recovery, and hormonal balance. Dosing context, safety notes, and who each is best for.

Last updated: June 3, 2026

The best peptides for women span a wide range of goals, from gut healing and joint repair to visceral fat reduction and skin anti-aging. BPC-157 is our top overall pick: a 15-amino-acid compound derived from human gastric protein that supports collagen synthesis, gut barrier integrity, and connective tissue repair across multiple systems simultaneously, with a favorable preclinical tolerability profile. For women focused specifically on fat loss, AOD-9604 stands out because it targets lipolysis in visceral and subcutaneous adipose tissue through beta-3 adrenergic receptor activation without raising IGF-1, triggering androgenic side effects, or disrupting an already fluctuating hormonal environment.

In addition to our research, our team evaluated 7 peptides used in women's health protocols to confirm our top 7 list. Rankings are based on the following criteria: we evaluated clinical evidence and mechanism of action as it applies to female physiology; we assessed frequency of use across women's health and functional medicine sources; we reviewed safety profiles and contraindications specific to women, including perimenopause, HRT use, and hormonal context; we compared typical dosing protocols available from licensed compounding and telehealth providers; and we cross-referenced coverage across peer-reviewed citations and clinical guidance pages. We evaluated over 20 peptide compounds sourced from PubMed clinical literature and major telehealth provider formularies.

Best Peptides for Women at a Glance

Use this table to compare all 7 peptides by primary benefit, ideal user, and administration route before diving into the full reviews below.

List of the 7 Best Peptides for Women

1. BPC-157

Best for: gut healing and joint repair

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, a chain of 15 amino acids, derived from a protein found in human gastric juice. It promotes tissue repair through several mechanisms: it stimulates fibroblast proliferation and collagen synthesis, upregulates growth hormone receptor expression in tendon cells via JAK2 signaling, promotes angiogenesis through VEGFR2-Akt-eNOS pathways, and stabilizes tight junction proteins (ZO-1, occludin, claudin) in the gut lining to reduce intestinal permeability. Research is primarily preclinical (animal models), with very limited human trial data available.

Why it works for women: As estrogen declines during perimenopause and menopause, women experience accelerated connective tissue degradation, increased gut permeability, and slower muscle and tendon recovery, all areas where BPC-157's mechanisms are most studied. Estrogen normally supports collagen integrity and gut barrier function; as levels fall, the compounding effects of reduced collagen turnover and increased intestinal permeability become more prominent, making the peptide's proposed collagen-stimulating and tight-junction-stabilizing actions particularly relevant to this population. Additionally, the gut-hormone axis means that improved gut barrier function may indirectly support more stable hormone metabolism.

Common uses in women:

Typical dosing range: 200-500 mcg injected subcutaneously once daily, administered near the site of injury or in the abdomen; oral formulations are used at 250-500 mcg once to twice daily for gut-focused applications. Cycle length in clinical compounding contexts is typically 4-6 weeks for musculoskeletal goals or 4-8 weeks for gastrointestinal repair. Consult a licensed provider before starting, no validated human dosing standard exists and protocols vary by indication.

Pros:

Cons:

Safety note: BPC-157 should not be used during pregnancy or breastfeeding, no safety data exists in these populations and its angiogenic and growth-promoting mechanisms pose theoretical risks to fetal development. Women with active or prior hormone-sensitive cancers should also avoid use, as BPC-157's pro-angiogenic effects could theoretically support tumor vascularization; individuals with serious liver, kidney, or endocrine disorders should consult a specialist before considering it (American Wellness Pharmacy compounding reference; inovifertility.com clinical overview).

2. CJC-1295 + Ipamorelin

Best for: body composition and sleep quality

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that binds to GHRH receptors on pituitary somatotroph cells, stimulating growth hormone (GH) synthesis and release. Ipamorelin is a selective ghrelin mimetic that binds to the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, triggering a rapid, clean GH pulse without raising cortisol or prolactin. Used together, the two peptides act on distinct receptor pathways and produce a synergistic effect, clinical practice sources describe a 3-5 fold increase in GH release compared to either compound alone, with CJC-1295 sustaining elevated GH levels over hours and Ipamorelin providing the initial pulse.

Why it works for women: GH secretion declines roughly 14% per decade after age 30, and this decline accelerates during perimenopause as estrogen, which normally amplifies pituitary GH pulses, falls. The overlap of dropping estrogen and dropping GH compounds changes in body composition (visceral fat gain, lean mass loss), sleep architecture, and skin quality that women in their 40s and 50s commonly report. By stimulating the pituitary's own GH release rather than supplying exogenous HGH, CJC-1295 + Ipamorelin works within the body's feedback loop, which helps preserve pulsatile GH patterns and reduces the risk of suppressing endogenous production.

Common uses in women:

Typical dosing range: 100-300 mcg of each peptide (CJC-1295 and Ipamorelin) injected subcutaneously once daily, typically before bed on an empty stomach (at least 2 hours after eating); most compounding pharmacy protocols start women at 100-150 mcg each daily and titrate to 200 mcg each over 4-8 weeks based on response and lab monitoring; common cycling protocol is 3 months on, 1 month off. Always consult a licensed provider before starting; these peptides are available only through a prescription and an accredited compounding pharmacy.

Pros:

Cons:

Safety note: CJC-1295 + Ipamorelin should be avoided by anyone who is pregnant, breastfeeding, or has an active cancer diagnosis or personal history of cancer, as elevated IGF-1 may theoretically promote tumor growth. Women on hormone replacement therapy or other hormonal medications should have their full hormone panel reviewed by a prescribing provider before starting, as concurrent hormonal therapies can alter the interaction profile. Rare but serious adverse events including immunogenicity reactions and cardiovascular effects (transient flushing, increased heart rate, vasodilation) have been reported with CJC-1295; source only through a licensed provider and accredited compounding pharmacy.

3. Sermorelin

Best for: growth hormone support and body composition

Sermorelin is a 29-amino acid synthetic peptide representing the 1-29 N-terminal fragment of endogenous human growth hormone-releasing hormone (GHRH). It binds to GHRH receptors in the anterior pituitary, stimulating the gland to produce and secrete its own growth hormone in discrete pulses, mimicking the body's natural pulsatile GH release pattern. Because it works through the pituitary's own feedback loop (regulated by IGF-1 and somatostatin), it preserves natural hormone regulation rather than bypassing it. The FDA approved sermorelin in 1997 for GH deficiency in children; commercial production was discontinued in 2008, and it is now available only through compounding pharmacies for off-label adult use.

Why it works for women: Natural growth hormone output declines approximately 14% per decade after age 30, with women experiencing a steeper functional drop during perimenopause due to the withdrawal of estrogen, which previously amplified GH pulses. This decline contributes to increased visceral fat accumulation, loss of lean muscle, reduced bone density, and disrupted sleep, all common perimenopausal complaints. Sermorelin addresses these downstream effects by restoring pituitary GH secretion without directly replacing estrogen or progesterone, making it a distinct adjunct to or alternative for women who cannot or choose not to use conventional HRT.

Common uses in women:

Typical dosing range: 200-500 mcg injected subcutaneously (abdomen or thigh, using an insulin syringe) nightly on an empty stomach, 5 out of 7 nights per week; some compounding pharmacy protocols use 0.15-0.3 mL of a 1 mg/mL formulation on the same schedule. Injections are timed 30-60 minutes before sleep, following at least 2 hours of fasting. Consult a licensed prescriber before starting, dosing is individualized based on age, body composition, and IGF-1 lab values.

Pros:

Cons:

Safety note: Sermorelin is contraindicated in individuals with active or suspected malignancy, as growth hormone can stimulate tumor growth. Women who are pregnant or breastfeeding, or who have untreated hypothyroidism, epilepsy, poorly controlled diabetes, or hyperglycemia should avoid use or consult their provider before starting.

4. GHK-Cu (Copper Peptide)

Best for: skin aging and hair thinning

GHK-Cu is a naturally occurring tripeptide, glycyl-L-histidyl-L-lysine, bound to a copper ion. It circulates in blood plasma, saliva, and urine, and functions as a master regulator of tissue remodeling: it stimulates fibroblasts to produce types I and III collagen and elastin, activates lysyl oxidase to cross-link those fibers into durable networks, and modulates over 4,000 human genes involved in repair, antioxidant defense, and stem cell activity. Plasma GHK-Cu levels decline roughly 60% between age 20 (approximately 200 ng/mL) and age 60 (approximately 80 ng/mL), creating a measurable deficit that coincides with accelerated tissue aging.

Why it works for women: In the first five years after menopause, women can lose up to 30% of their skin collagen due to falling estrogen, a rate of loss far steeper than general age-related decline. GHK-Cu addresses this directly by stimulating collagen production and activating epigenetic repair programs that estrogen would otherwise support. On the scalp, declining estrogen combined with relative androgen dominance triggers follicle miniaturization; GHK-Cu has been shown to reduce conversion of testosterone to DHT, the androgen responsible for follicle shrinkage, while extending the anagen (growth) phase of the hair cycle, making it relevant for the androgenic and hormonal hair thinning common in perimenopause and postmenopause.

Common uses in women:

Typical dosing range: Topical: 0.2-2% concentration applied once or twice daily to face or scalp; start at the lower end and increase based on tolerance over 3-6 months. Injectable: 0.5-2 mg subcutaneously once daily (off-label; no FDA-approved indication exists and injectable GHK-Cu was classified as a high-risk compounded substance by the FDA in September 2023, restricting 503A pharmacy compounding). Consult a licensed provider before starting any GHK-Cu protocol, particularly injectable forms.

Pros:

Cons:

Safety note: GHK-Cu is contraindicated in active or suspected cancer (it promotes angiogenesis, which could theoretically support tumor growth), Wilson's disease (a copper metabolism disorder), pregnancy, and breastfeeding (insufficient safety data). Avoid injectable formulations if using blood thinners or immunosuppressants without physician clearance.

5. AOD-9604

Best for: targeted fat loss without hormonal disruption

AOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal fragment (positions 176-191) of human growth hormone, with a stabilizing tyrosine added at the N-terminus. It was developed at Monash University in Australia in the 1990s specifically to isolate the fat-metabolizing activity of HGH. The peptide stimulates lipolysis (fat breakdown) and inhibits lipogenesis (new fat storage) by activating beta-3 adrenergic receptors in adipose tissue and modulating AMP-activated protein kinase (AMPK), a cellular energy regulator, without binding to the classical GH receptor or raising IGF-1 levels.

Why it works for women: As estrogen declines during perimenopause and menopause, the female body shifts fat storage toward the abdomen and becomes less responsive to catecholamine-driven lipolysis. AOD-9604 directly targets beta-3 adrenergic receptors in visceral and subcutaneous adipose tissue, the same fat depots that tend to accumulate during hormonal transitions, without triggering androgenic side effects (such as acne, hair thinning, or virilization) that can occur with full-length growth hormone or androgen-containing therapies. Because it does not alter IGF-1, cortisol, insulin sensitivity, or sex hormone levels, it integrates without disrupting an already fluctuating hormonal environment.

Common uses in women:

Typical dosing range: 250-500 mcg injected subcutaneously once daily, typically in the morning on an empty stomach; clinical trials evaluated doses of 250 mcg, 500 mcg, and 1,000 mcg daily over 24 weeks, with no additional benefit observed above 1,000 mcg. Prescribed and compounded by licensed providers, consult a licensed provider before starting.

Pros:

Cons:

Safety note: AOD-9604 should be avoided during pregnancy and breastfeeding, as no safety data exist for these populations. It should also be avoided in individuals with active malignancy or a history of cancer, as effects on tumor growth have not been studied; consult a licensed provider before use if you have any history of hormone-sensitive conditions or are currently taking HRT.

6. Tesamorelin

Best for: visceral belly fat in women

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 44 amino acids structurally identical to endogenous human GHRH, modified with a trans-3-hexenoic acid group that extends its half-life from under 10 minutes to approximately 26-38 minutes. It binds to GHRH receptors on somatotroph cells in the anterior pituitary, triggering cAMP/PKA signaling that stimulates pulsatile growth hormone secretion, preserving natural hypothalamic feedback rather than flooding the system with exogenous GH. The resulting GH pulses then stimulate hepatic IGF-1 production, which drives lipolysis preferentially in visceral adipose tissue (VAT), where GH receptor concentrations are higher than in subcutaneous fat.

Why it works for women: Estrogen normally suppresses visceral adipocyte hypertrophy; as estrogen declines during perimenopause and menopause, fat distribution shifts from gynoid (hips, thighs) to android (abdominal) patterns even without total weight gain. Endogenous GH secretion also declines approximately 14% per decade after age 30, compounding the VAT accumulation problem. Tesamorelin restores GH pulsatility through the pituitary axis, targeting the VAT deposits that lifestyle modifications alone often fail to address in this hormonal context.

Common uses in women:

Typical dosing range: 2 mg injected subcutaneously once daily (typically at bedtime, into the abdominal wall away from the navel); some compounding protocols run 5 days on / 2 days off in 3-month cycles. The 2 mg fixed dose is the FDA-approved amount for the HIV lipodystrophy indication; off-label compounding protocols may vary. Always consult a licensed provider before starting.

Pros:

Cons:

Safety note: Tesamorelin is contraindicated in pregnancy (classified Pregnancy Category X; may harm the fetus) and should not be used while breastfeeding. It is also contraindicated in anyone with an active malignancy, a history of pituitary tumors, prior head or brain radiation, or hypopituitarism, because stimulating the GH-IGF-1 axis carries a theoretical risk of accelerating tumor growth; any preexisting cancer must be fully inactive and treatment complete before starting. Women with pre-existing hyperglycemia or diabetes require close blood glucose monitoring, as tesamorelin can worsen glucose intolerance.

7. Kisspeptin

Best for: hormonal balance and fertility support

Kisspeptin is a neuropeptide encoded by the KISS1 gene that binds the GPR54 receptor (also called KISS1R) on hypothalamic neurons. Binding triggers pulsatile release of gonadotropin-releasing hormone (GnRH), which drives the downstream secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary. It functions as an upstream master regulator of the hypothalamic-pituitary-gonadal (HPG) axis and is considered essential for the onset and maintenance of reproductive function.

Why it works for women: Estrogen exerts positive feedback on KISS1 expression in the anteroventral periventricular nucleus (AVPV), a region that is sexually dimorphic and more highly expressed in females. This feedback drives the pre-ovulatory LH surge that triggers ovulation. During perimenopause, falling estrogen levels destabilize GnRH pulsatility, and research published in PMC (2009) found that kisspeptin/neurokinin B neurons in the hypothalamus are directly implicated in that HPG axis instability. A study in postmenopausal women (Journal of Clinical Endocrinology & Metabolism, 2017) showed that continuous kisspeptin infusion still stimulated LH secretion, with response magnitude dependent on estradiol levels, indicating the pathway remains at least partially responsive even after menopause.

Common uses in women:

Typical dosing range: In IVF clinical trials, kisspeptin-54 was administered as a single subcutaneous injection at 9.6 nmol/kg approximately 36 hours before oocyte retrieval, sometimes followed by a second dose 10 hours later. Compounding pharmacy protocols for general hormonal use have cited 100-200 mcg subcutaneously once daily with 8-12 week cycles, though this is not derived from large RCT data. As of 2026, no kisspeptin formulation is FDA-approved, and the FDA Pharmacy Compounding Advisory Committee voted against adding kisspeptin-10 to the 503A Bulks List. Consult a licensed provider before starting any kisspeptin protocol.

Pros:

Cons:

Safety note: Women with hormone-sensitive cancers (including certain breast, ovarian, or endometrial cancers) should avoid kisspeptin, as it drives upstream sex hormone signaling and could theoretically influence estrogen-dependent tumor behavior. Use during pregnancy or breastfeeding has not been established and should be avoided without direct medical supervision.

How to Choose the Right Peptide for Your Goals

Match the Peptide to Your Primary Goal

Women focused on fat loss and body recomposition have two strong options depending on where the fat is distributed and what the hormonal backdrop looks like. AOD-9604 directly targets visceral and subcutaneous fat depots by activating beta-3 adrenergic receptors and modulating AMPK, without raising IGF-1 or triggering androgenic side effects, which makes it a practical fit for women seeking peptides for weight loss women-specific goals during hormonal transitions. Tesamorelin addresses the same problem from the pituitary axis: it restores pulsatile GH secretion, which drives preferential lipolysis in visceral adipose tissue where GH receptor concentrations are highest. A 26-week clinical trial found Tesamorelin produced a 15.2% reduction in visceral adipose tissue versus 4.3% with placebo, making it the option with the strongest controlled evidence for abdominal fat specifically.

For anti-aging and skin health, GHK-Cu and CJC-1295 + Ipamorelin address different layers of the same problem. GHK-Cu is a naturally occurring copper-bound tripeptide that stimulates fibroblasts to produce collagen and elastin, and a clinical trial of 21 women showed a mean 28% increase in collagen density after 3 months of daily topical use. CJC-1295 + Ipamorelin works more broadly: by synergistically amplifying pituitary GH release, it drives IGF-1-mediated tissue repair that improves skin elasticity, hair thickness, and nail strength alongside body composition changes.

BPC-157 is the primary choice for recovery, gut health, and joint support. It stabilizes tight-junction proteins in the gut lining, stimulates fibroblast proliferation and collagen synthesis in connective tissue, and promotes angiogenesis in healing tissue. For women experiencing faster tendon recovery times, increased gut permeability, or chronic joint pain tied to declining estrogen, BPC-157 addresses several overlapping issues within a single compound. Its oral stability in gastric juice is also notable: it is one of the few peptides that retains activity when taken by mouth, making it an option for gut-focused applications without requiring injection.

For hormonal balance and sleep, Sermorelin and Kisspeptin operate at different points in the signaling chain. Sermorelin stimulates pulsatile GH release through the pituitary, and the downstream effects include improved deep sleep, better body composition, and bone density support: postmenopausal women receiving GH in studies showed up to 14% increases in bone mineral content. Kisspeptin works upstream at the hypothalamic level, supporting GnRH and LH pulsatility when the HPG axis becomes unstable during perimenopause. A 2022 JAMA Network Open randomized trial also found kisspeptin modulated brain processing of sexual and attraction stimuli, suggesting a role in hypoactive sexual desire disorder alongside its hormonal stabilization function.

Age and Hormonal Status Matter

Perimenopause and post-menopause shift the entire landscape of which peptides are most relevant, because estrogen withdrawal compounds natural GH decline. Natural GH output falls approximately 14% per decade after age 30, and that rate accelerates during perimenopause as estrogen, which normally amplifies pituitary GH pulses, withdraws. For the best peptides for women over 40, growth hormone secretagogues including CJC-1295 + Ipamorelin and Sermorelin are frequently prioritized by functional medicine providers because they restore pulsatile GH within the body's own feedback loop rather than bypassing it. Women in this life stage dealing with visceral fat accumulation, lean mass loss, disrupted sleep, and skin changes often find that targeting GH signaling addresses several of those symptoms simultaneously.

Injection vs. Oral vs. Topical

Subcutaneous injection is the most common administration route for systemic peptides in this article, including Tesamorelin (2 mg nightly), Sermorelin (200-500 mcg nightly), CJC-1295 + Ipamorelin (100-300 mcg each, nightly), and AOD-9604 (250-500 mcg daily), because injection bypasses gastric degradation and delivers predictable plasma concentrations. Oral delivery is a practical alternative for BPC-157 when the goal is gut-specific: BPC-157 retains activity in gastric juice, and compounding protocols use 250-500 mcg once to twice daily for gastrointestinal applications. Topical application is the primary route for GHK-Cu, where 0.2-2% concentrations applied to the face or scalp daily have demonstrated measurable clinical effects on collagen density and wrinkle depth without requiring injection.

Are Peptides Safe for Women?

The peptides covered in this article are generally non-androgenic, meaning they do not carry the virilizing side effects associated with anabolic steroids or full-length growth hormone therapy. Most have favorable short-term safety profiles at clinical doses, with the strongest tolerability records belonging to compounds that have at least some human trial data, such as Tesamorelin and AOD-9604. Long-term human safety data is still limited or absent for several compounds, including BPC-157, Kisspeptin, and GHK-Cu in injectable form, so all use should be approached through licensed clinical oversight rather than self-directed protocols.

Who Should Avoid Peptides

Common Side Effects to Know

Most peptides covered here are not FDA-approved for general wellness use in healthy individuals; Tesamorelin is the sole exception, approved only for HIV-associated lipodystrophy. Several compounds, including BPC-157 and Kisspeptin, are classified as research chemicals in the United States, and legal access and compounding status vary significantly by country.

Frequently Asked Questions

What peptides should women take?

The right peptide depends on the primary goal. Women focused on fat loss tend toward AOD-9604 or Tesamorelin, which target visceral and abdominal fat through distinct mechanisms without androgenic side effects. Women prioritizing anti-aging and skin health often use GHK-Cu or CJC-1295 + Ipamorelin, while BPC-157 serves as a broad-spectrum option for gut health, joint repair, and recovery. A licensed provider can match the best option to individual hormonal status and health history.

What is the best peptide for belly fat in women?

AOD-9604 and Tesamorelin are the most studied peptides for abdominal fat in women. Tesamorelin has the strongest clinical backing, with a 26-week trial showing 15.2% visceral adipose tissue reduction versus 4.3% with placebo. A 2019 JCEM study in women with metabolic syndrome showed an 11.8% visceral fat reduction at 2 mg daily. Both require medical oversight and work best alongside resistance training and dietary changes.

What peptide works like Ozempic?

Semaglutide (Ozempic) is itself a GLP-1 receptor agonist peptide available only by prescription. Among compounds covered in this article, AOD-9604 targets fat metabolism by activating beta-3 adrenergic receptors and modulating AMPK, a cellular energy regulator, without binding the GH receptor or raising IGF-1. CJC-1295 + Ipamorelin supports body recomposition through growth hormone pathways. Neither replicates Ozempic's direct GLP-1 mechanism, and neither is available without a prescription from a licensed provider.

Are peptides safe for women over 40?

Many peptides used in women's health protocols are considered well-tolerated at clinical doses for women over 40, particularly growth hormone secretagogues like Sermorelin and CJC-1295 + Ipamorelin, which work through the pituitary's own feedback loop rather than bypassing it with exogenous hormones. Safety depends on individual health status, current medications, and lab values including IGF-1. Women with hormone-sensitive conditions, active malignancy, or untreated hypothyroidism should consult a specialist before starting any peptide protocol.

What is the best peptide for anti-aging in women?

GHK-Cu is one of the most studied peptides for skin anti-aging, with a clinical trial of 40 women aged 40 to 65 showing a 55.8% reduction in wrinkle volume and 32.8% reduction in wrinkle depth after 8 weeks of topical use. CJC-1295 + Ipamorelin supports anti-aging more broadly by restoring growth hormone pulse amplitude, which declines roughly 14% per decade after age 30. Both are used in clinical protocols as part of the best peptides for anti aging women strategies, targeting collagen, body composition, and tissue repair.

Do peptides interact with HRT?

Some peptides can be used alongside hormone replacement therapy with proper provider coordination, but the combination requires careful review. Kisspeptin and Sermorelin both act on the hypothalamic-pituitary axis, the same signaling pathway that HRT influences, and introducing them alongside estrogen or progesterone therapy can alter the hormonal interaction profile. GHK-Cu is a notable exception, as its non-hormonal collagen-stimulating mechanism means it can generally be layered with HRT without interaction concerns. A prescribing provider should review all current medications before combining peptide therapy with HRT.

Our Final Recommendation

The best peptides for women depend on your primary goal and hormonal stage. BPC-157 is the broadest starting point for recovery, gut health, and connective tissue support. For fat loss, AOD-9604 and Tesamorelin offer the most targeted metabolic mechanisms. Women in perimenopause or post-menopause prioritizing body composition and sleep will find the most evidence behind CJC-1295 + Ipamorelin and Sermorelin. GHK-Cu remains the go-to for topical skin anti-aging. Whatever the goal, work with a licensed provider to confirm the right protocol for your individual health status before starting.

Disclaimer

The information provided on Peptide Mind is for educational purposes only and is not a substitute for professional medical advice. Many peptides discussed on this site are unapproved research chemicals intended strictly for laboratory and preclinical use. Furthermore, any dosage calculator provided is a theoretical tool for math visualization and does not represent medical dosing instructions. The FDA has not evaluated these statements, and nothing on this site is intended to diagnose, treat, cure, or prevent any disease. By accessing this site, you confirm you are over the age of 21, waive any claims or liability arising from the use of the content portrayed, and fully indemnify Peptide Mind against any unauthorized usage, claims, or liability in accordance with our Terms of Service.